Amgen Embarks on Major $650 Million Expansion in U.S. Manufacturing Sector

Amgen’s Bold Move: $650 Million Expansion of U.S. Manufacturing

Amgen, the renowned biopharmaceutical company based in Thousand Oaks, California, has recently unveiled an exciting plan to invest $650 million into expanding its manufacturing capabilities within the United States. The announcement was made on September 26, 2025, signaling the company's ongoing commitment to strengthening its operations and ensuring a robust supply chain. With this expansion, Amgen anticipates creating approximately 750 jobs—an important boost to the local economy.

The investment is earmarked for enhancing production at Amgen’s biologics manufacturing facility located in Juncos, Puerto Rico. This facility will integrate cutting-edge technologies into its operations, allowing for a more efficient and innovative production process. Amgen’s CEO, Robert A. Bradway, stated, “This expansion underscores Amgen's commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain.” He emphasized that increasing production capacity will not only enhance patient service but also generate high-quality job opportunities, thereby reinforcing American leadership in biotechnology.

Furthermore, the Governor of Puerto Rico, Jenniffer González Colón, expressed her enthusiasm about the expansion. She highlighted that the project reflects a mutual dedication between Amgen and Puerto Rico’s skilled workforce, thereby strengthening supply chain security through reshoring. “This new expansion not only strengthens U.S. supply chain security through reshoring,” she stated, “it also opens new horizons for our people as we build an innovation ecosystem that positions Puerto Rico as the strongest biopharmaceutical hub in the United States.”

Sebastián Negrón Reichard, the Puerto Rico Secretary of the Department of Economic Development and Commerce, added that Puerto Rico boasts over six decades of experience in the biopharmaceutical sector and is supported by a highly skilled talent pool and world-class infrastructure. This new investment by Amgen stands as a testament to Puerto Rico’s dedication to fostering a competitive and innovative ecosystem for global companies.

Amgen’s history of investing in U.S. innovation is significant, surpassing $40 billion in manufacturing and R&D expenditures since the Tax Cuts and Jobs Act (TCJA) was enacted in 2017. The recent extension of pro-growth tax policies, further reinforced by the One Big Beautiful Bill Act of 2025, has allowed Amgen to ramp up its domestic investments in advanced science and manufacturing practices.

The recent announcement comes amid Amgen's ongoing commitment to growth, following earlier investments including a $600 million science and innovation center in California and manufacturing expansions of $900 million in Ohio, and $1 billion in North Carolina.

Beyond manufacturing, Amgen is recognized for its pioneering work in biotechnology, discovering, developing, and delivering innovative medicines that address some of the most challenging diseases patients face. With a track record that stretches back over 40 years, Amgen has played a significant role in shaping the biotechnology industry. Its commitment to technology and human genetic data fundamentally advances its scientific endeavors, continually leading to groundbreaking discoveries.

Fast Company recognized Amgen as one of the “World's Most Innovative Companies” in 2024, and Forbes listed it among “America's Best Large Employers.” These accolades underscore Amgen's status within the healthcare industry and its pivotal role in the biotechnology sector, evidenced further by its inclusion in both the Dow Jones Industrial Average® and the Nasdaq-100 Index®, signifying its position as one of the largest and most innovative companies.

In conclusion, Amgen's $650 million expansion represents a strategic move not only to bolster its manufacturing capabilities and workforce but also to ensure that it remains at the forefront of innovation in the biopharmaceutical industry. This initiative will not just contribute to the jobs market but is also poised to enhance healthcare delivery across the United States, affirming Amgen's vital role in promoting patient care and advancing medical research.